Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System

Real-world pharmacovigilance evidence indicates that thromboembolic event reporting for TPO-RAs shows drug-specific patterns, with venous events predominating and a notable fraction occurring early after treatment initiation. Patients of very advanced age, those with higher body weight, and those receiving prolonged therapy appear particularly vulnerable, supporting proactive baseline risk stratification and sustained thrombosis surveillance throughout treatment.